The serum alkaline phosphatase ( ALP ) levels and the Mayo risk score in the combination therapy group ( mean 290IU/l and 0.91 , respectively ) were significantly lower than those in the UDCA monotherapy group ( mean 461IU/l and 1.42 , respectively ) at 8 years after the beginning of the study ( P < 0.05 ) .